Cargando…

Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial

OBJECTIVE: To evaluate baseline characteristics predictive of improving information processing speed in multiple sclerosis (MS) and the relationship between cognitive and motor response to dalfampridine (DA) treatment. METHODS: This is a post hoc analysis of a randomized, double-blind, placebo-contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pozzilli, Carlo, Prosperini, Luca, Tommasin, Silvia, Gasperini, Claudio, Barbuti, Elena, De Giglio, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072854/ https://www.ncbi.nlm.nih.gov/pubmed/34035835 http://dx.doi.org/10.1177/17562864211011286

Ejemplares similares

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2020)

The added value of spinal cord lesions to disability accrual in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2023)

Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)

Predicting the profile of increasing disability in multiple sclerosis
por: Tomassini, Valentina, et al.
Publicado: (2018)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis
por: Shi, Jianzhen, et al.
Publicado: (2019)

A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2021)

Eating Hubs in Multiple Sclerosis: Exploring the Relationship Between Mediterranean Diet and Disability Status in Italy
por: Felicetti, Federica, et al.
Publicado: (2022)

The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review
por: Prosperini, Luca, et al.
Publicado: (2013)

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
por: Prosperini, Luca, et al.
Publicado: (2011)

Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases
por: Nistri, Riccardo, et al.
Publicado: (2021)

Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis
por: Tommasin, Silvia, et al.
Publicado: (2021)

Assessing the Correlation between Grey and White Matter Damage with Motor and Cognitive Impairment in Multiple Sclerosis Patients
por: Sbardella, Emilia, et al.
Publicado: (2013)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability
por: Tommasin, Silvia, et al.
Publicado: (2022)

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques
por: Taloni, Alessandro, et al.
Publicado: (2022)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Motor Fatigue Measurement by Distance-Induced Slow Down of Walking Speed in Multiple Sclerosis
por: Phan-Ba, Rémy, et al.
Publicado: (2012)

Walking characteristics including mild motor paralysis and slow walking speed in post-stroke patients
por: Mizuta, Naomichi, et al.
Publicado: (2020)

Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies
por: Prosperini, Luca, et al.
Publicado: (2022)

Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Increased risk of death from COVID-19 in multiple sclerosis: A meta-analysis of observational studies
por: Prosperini, Luca, et al.
Publicado: (2021)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018)

Dalfampridine Prior Authorization Program: A Cohort Study
por: Gleason, Patrick P., et al.
Publicado: (2013)

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program
por: Crayton, Heidi, et al.
Publicado: (2014)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
por: Jara, Michele, et al.
Publicado: (2014)

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
por: Sadeqi, Yasaman, et al.
Publicado: (2022)

Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients
por: Piervincenzi, Claudia, et al.
Publicado: (2021)

Functional and Structural Brain Plasticity Enhanced by Motor and Cognitive Rehabilitation in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2015)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9cc1ice7qc27mjug6ivqng6k0n